Clinical enrollment concludes for Spark Biomedical’s pivotal trial investigating a non-invasive, drug-free neurostimulation treatment for newborns born with NOWS.
New Health Canada Approval Allows Spark Biomedical to Offer Drug-Free Opioid Withdrawal Relief Across Canada.
This trial will test the feasibility of wearable neurostimulation to help reduce fatal disorientation-related errors in the military.
